Expiry Date March 2024
SaNOtize Nasal Spray
Sanotize Nitric Oxide Nasal Spray (NONS) - Your Daily Protection Against Viruses
Buy Now!
Free Delivery
WORLDWIDE EXPEDITED DELIVERY
Customer Reviews
Why Sanotize?
Phase 3 Clinical Trial Confirms
SaNOtize’s Treatment is 99% Effective
Against COVID-19!
On Feb 9, 2022 SaNOtize announced the completion of Phase 3 trial in India for its nitric oxide nasal spray. The trial reached primary endpoint:
Reduction in SARS-CoV-2 log viral load in COVID-19 patients by more than 94% within 24 hours of treatment, and by more than 99% in 48 hours
The double-blind, parallel arm, multicenter study, conducted in 306 patients in non-hospitalized adult patients. NONS was safe and well tolerated by patients. No patients experienced moderate, severe, serious Adverse Events (AE) or death in the study.
Enovid News
Gilly Regev and Chris Miller write about The Power of Nitric Oxide on MedCityNews.com
"The Power of NO: How a Tiny Natural Molecule Can Help Shift How We Treat...
Read more
The Jerusalem Post: Can an anti-viral nasal spray stop Corona and other viruses?
"Enovid, an innovative anti-viral spray developed in Canada by an Israeli researcher and manufactured in...
Read more
SaNOtize moves to carve a new market demand: over-the-counter prevention
There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian...
Read more
SaNOtize raised $24M to fund phase 3 trial of COVID-19 nasal spray
SaNOtize has raised a $24 million series B round, giving it the cash to fund its...
Read more
Clinical Study Suggests SaNOtize Nitric Oxide Nasal Spray Is Effective at Preventing COVID-19 after High-Risk Exposure
Published on May 11, 2022 on Businesswire.com. After confirmed exposure to COVID-19, infection rate in...
Read more
Phase 3 Clinical Trial Confirms SaNOtize’s Treatment is 99% Effective Against COVID-19
SaNOtize and Glenmark Pharmaceuticals Limited has announced on February 09, 2022: Phase 3 trial reached primary...
Read more
Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company
Amorphical, an Israeli biotech company developing Amorphous Calcium Carbonate (ACC) has announced results of a...
Read more